Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives $37.60 Average Target Price from Brokerages

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) has received a consensus rating of "Moderate Buy" from the twelve analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $37.80.

A number of brokerages recently issued reports on GMAB. Truist Financial raised their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday. Sanford C. Bernstein downgraded shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. Wall Street Zen downgraded Genmab A/S from a "buy" rating to a "hold" rating in a research note on Saturday, June 14th. Finally, HC Wainwright restated a "buy" rating and issued a $37.00 price objective (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th.

Institutional Trading of Genmab A/S

Several hedge funds and other institutional investors have recently modified their holdings of the business. Raymond James Financial Inc. purchased a new stake in shares of Genmab A/S during the fourth quarter worth $2,463,000. Northern Trust Corp boosted its stake in Genmab A/S by 18.8% in the 4th quarter. Northern Trust Corp now owns 599,381 shares of the company's stock worth $12,509,000 after purchasing an additional 94,858 shares during the period. GAMMA Investing LLC grew its holdings in Genmab A/S by 1,465.3% during the 1st quarter. GAMMA Investing LLC now owns 33,482 shares of the company's stock valued at $656,000 after buying an additional 31,343 shares in the last quarter. Sei Investments Co. increased its position in shares of Genmab A/S by 55.2% during the fourth quarter. Sei Investments Co. now owns 57,702 shares of the company's stock valued at $1,205,000 after buying an additional 20,525 shares during the period. Finally, LPL Financial LLC lifted its holdings in shares of Genmab A/S by 3.3% in the fourth quarter. LPL Financial LLC now owns 195,436 shares of the company's stock worth $4,079,000 after buying an additional 6,288 shares in the last quarter. Institutional investors own 7.07% of the company's stock.

Genmab A/S Price Performance

GMAB stock traded down $0.46 during trading on Tuesday, reaching $21.40. 1,247,549 shares of the company were exchanged, compared to its average volume of 1,247,364. The company has a market capitalization of $13.73 billion, a price-to-earnings ratio of 12.16, a P/E/G ratio of 6.56 and a beta of 0.94. The company has a 50-day moving average of $21.04 and a two-hundred day moving average of $20.74. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $28.56.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.08. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. The company had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion. On average, analysts forecast that Genmab A/S will post 1.45 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.